Piper Sandler analyst David Westenberg downgraded Exact Sciences (EXAS) to Neutral from Overweight with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Booking, Carvana upgraded: Wall Street’s top analyst calls
- Exact Sciences downgraded to Hold from Buy at Benchmark
- Exact Sciences downgraded to Hold from Buy at Jefferies
- Exact Sciences Downgraded to Hold Amid ABT Acquisition and Market Uncertainties
- Cathie Wood Loads Up on CoreWeave (CRWV), and Crypto Stocks; Trims Stakes in GitLab, AMD, and Other Tech Stocks